---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023200"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2026-05-14T21:26:31+00:00"
generated_at: "2026-05-14T21:28:12.970435+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform

## Summary
- Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.
- Unregistered warrants have exercise price $2.27, exercisable after 6 months, expire 5 years from initial exercise.
- Up to additional $4.85M gross proceeds if warrants fully exercised; no assurance of exercise.
- Company plans to separate AI platform withZeta.ai into independent entity; may become publicly listed.
- Suspended ATM sales under July 2025 agreement with ThinkEquity; agreement remains in effect.

## SEC filing metadata
- accession: 0001493152-26-023200
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2026-05-14T21:26:31+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/0001493152-26-023200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023200
- JSON: https://secwatch.observer/filing/0001493152-26-023200.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023200.txt

## Key facts
- Material Agreements
  Lantern Pharma Inc. entered into Purchase Agreement with institutional investors valued at approximately $4.4 million (effective 2026-05-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: institutional investors
  - Value: approximately $4.4 million
  - Effective: 2026-05-12
  source text: On May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/0001493152-26-023200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.